ABC7-Konsens zur Systemtherapie des fortgeschrittenen Mammakarzinoms-Reference-Cited by-同舟云学术

ABC7-Konsens zur Systemtherapie des fortgeschrittenen Mammakarzinoms

Published:2024-09-13 Issue: Volume: Page:
ISSN:2731-7226
Container-title:Die Onkologie
language:de
Short-container-title:Onkologie

Author:

Lüftner Diana,Ditsch Nina,Fasching Peter A.,Busch Steffi,Ettl Johannes,Haidinger Renate,Jackisch Christian,Müller Lothar,Müller Volkmar,Ruckhäberle Eugen,Schumacher-Wulf Eva,Thomssen Christoph,Untch Michael,Wuerstlein Rachel,Harbeck Nadia

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s00761-024-01588-x.pdf

Reference29 articles.

1. André F, Park HY, Kim S‑B et al (2023) Trastuzumab deruxtecan versus treatment of physician’s choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): a randomised, open-label, multicentre, phase 3 trial. Lancet 401(10390):1773–1785

2. Azim H, El Saghir NS, Yap Yea (2023) First-line ribociclib + endocrine therapy vs combination chemotherapy in aggressive HR+/HER2- advanced breast cancer: a sub-group analysis of patients with or without visceral crisis from the phase II RIGHT Choice study. Präsentation 402P. https://oncologypro.esmo.org/meeting-resources/esmo-congress. Zugegriffen: 27. Nov. 2023

3. Bardia A, Hurvitz SA, Tolaney SM et al (2021) Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer. N Engl J Med 384(16):1529–1541

4. Bidard F‑C, Kaklamani VG, Neven P et al (2022) Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2‑Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial. J Clin Oncol 40(28):3246–3256

5. Biganzoli L, Battisti NML, Wildiers H et al (2021) Updated recommendations regarding the management of older patients with breast cancer: a joint paper from the European Society of Breast Cancer Specialists (EUSOMA) and the International Society of Geriatric Oncology (SIOG). Lancet Oncol 22(7):e327–e340